ArticleEJHaem2026
Inhibitory HLA-C/KIR2DL2 Interactions and KIR Allelic Polymorphisms Are Associated With Susceptibility to Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune surveillance is increasingly recognized as a determinant of clonal selection in Philadelphia chromosome-negative myeloproliferative neoplasms (MPN). While HLA-restricted adaptive immune effects have been described, the contribution of inherited variation in natural killer (NK)-cell regulatory pathways remains less well defined. We investigated whether killer immunoglobulin-like receptor (KIR) allelic polymorphisms and HLA-KIR receptor-ligand interactions are associated with susceptibility to MPN. Methods: We performed high-resolution next-generation sequencing-based KIR genotyping in 167 Bulgarian patients with Philadelphia chromosome-negative MPN, including 137 with JAK2 V617F-positive disease and 30 with CALR-mutated disease, and in 97 healthy controls. All subjects had prior high-resolution typing for HLA-A, -B, and -C. Associations between KIR alleles and disease status were evaluated using additive generalized linear models adjusted for age and sex. HLA-KIR receptor-ligand interactions were analyzed using biologically defined interaction models. Results: Several KIR allelic associations with MPN susceptibility were identified, although some involved low-frequency variants. Across analyses, the most consistent finding was that inhibitory KIR2DL2, together with HLA-C2 ligands, was associated with increased susceptibility to MPN overall and within mutation-defined subgroups, with the strongest signal observed in CALR-mutated disease. In contrast, the absence of KIR2DL2 was associated with a lower risk in both JAK2 V617F-positive and CALR-mutated MPN. These findings are consistent with a model in which inherited inhibitory NK-cell signaling may influence early immune escape of emerging mutant clones. Conclusion: Inherited variation in KIR genes and HLA-KIR inhibitory interactions may contribute to susceptibility to Philadelphia chromosome-negative MPN. The findings support a possible role for NK-cell regulatory pathways in early MPN pathogenesis, but should be considered hypothesis-generating and require validation in larger independent cohorts. Trial Registration: The author has confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.